Michael D. Devous

Dr. Devous recently retired as Vice President of Imaging Development at Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company. His responsibilities included serving on the Executive Committee, directing the Imaging Sciences Department, and designing, executing, analyzing, and interpreting clinical trials. He also assisted in development and implementation of online and in-person training for the use of imaging biomarkers. He also served on clinical trial design, analysis, and interpretation teams for therapeutics developed by Eli Lilly and Company with a focus on imaging and non-imaging (e.g., plasma) biomarkers and their role in therapeutic clinical trials. He was also previously Professor of Radiology, Neurology, and Bioengineering, Director of the Alzheimer’s Disease Center Neuroimaging Core, Co-Principal Investigator of the North Texas Traumatic Brain Injury Model System, and Associate Director of the Nuclear Medicine Center at the University of Texas Southwestern Medical Center, Dallas, Texas. He remains an Adjunct Professor of Neurology at UT Southwestern and of Behavioral and Brain Sciences at the University of Texas at Dallas. He has authored more than 200 peer-reviewed articles, 375 abstracts, and 30 books or book chapters. Dr. Devous is past president of the Society of Nuclear Medicine, the Education and Research Foundation, and the Brain Imaging Council. He is a former chair of the Food and Drug Administration Medical Imaging Drugs Advisory Committee. He has received numerous awards, including: Presidential Distinguished Service Award - Society of Nuclear Medicine; Scientific Merit First Award - American Speech, Language and Hearing Association; and the Kuhl-Lassen Award, the highest award of the Brain Imaging Council and the Society of Nuclear Medicine. His research focuses on advancing understanding of the pathobiology of neurologic and psychiatric disorders, and normal brain function, through molecular, functional, and structural neuroimaging techniques.